Justmet V 50/500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby reducing blood glucose levels. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic control. The combination of these two agents offers complementary mechanisms of action, providing effective glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Justmet V 50/500 Tablet is typically administered once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to any component. Monitoring of renal function and blood glucose levels is recommended during therapy. This combination therapy may aid in achieving target glycemic goals while minimizing the risk of hypoglycemia. Patients should be counseled on lifestyle modifications alongside pharmacotherapy for optimal diabetes management.